Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy

Experimental Biology and Medicine

Volumn 235, Issue 11, 2010, Pages 1338-1346

  Sukumaran, Vijayakumar ^a   Watanabe, Kenichi ^a   Veeraveedu, Punniyakoti T ^a,b   Thandavarayan, Rajarajan A ^a   Gurusamy, Narasimman ^c   Meilei, Ma ^a   Yamaguchi, Ken'ichi ^d   Suzuki, Kenji ^d   Kodama, Makoto ^d   Aizawa, Yoshifusa ^d  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Angiotensin II; Cardiac remodeling; Dilated cardiomyopathy; Fibrosis; Olmesartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CARDIAC MYOSIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MOLECULAR MARKER; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; TRANSFORMING GROWTH FACTOR BETA1;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE REMODELING; HEART MUSCLE FIBROSIS; HEMODYNAMIC PARAMETERS; IMMUNIZATION; INFLAMMATION; LEWIS RAT; MALE; MYOCARDITIS; NONHUMAN; PROTEIN EXPRESSION; RAT; SURVIVAL; TISSUE REPAIR;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOMYOPATHY, DILATED; CHEMOKINE CCL2; IMIDAZOLES; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDITIS; MYOCARDIUM; MYOSINS; RATS; RATS, INBRED LEW; RNA, MESSENGER; TETRAZOLES; VENTRICULAR REMODELING;

RATTUS;

EID: 78049322900     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2010.010016     Document Type: Article

References (41)

1. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990;57:250-62
2. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-84
3. Cohn JN, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75 (Pubitemid 33126822)
4. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet 2002;359:1004-10
5. Yuan Z, Nimata M, Okabe TA, Shioji K, Hasegawa K, Kita T, Kishimoto C. Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol 2005;289:H1147-52
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65
7. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999;79:215-62
8. Powell JS, Clozel JP, Müller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8 (Pubitemid 19193936)
9. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth. A link to cardiovascular hypertrophy? J Hypertens 1991;9:3-15
10. Fliser D, Buchholz K, Haller H; EUTOPIA Investigators. Antiinflammatory effects of angiotensin subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7
11. Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res 2004;27:771-9
12. Yao L, Kobori H, Rahman M, Seth DM, Shokoji T, Fan Y, Zhang GX, Kimura S, Abe Y, Nishiyama A. Olmesartan improves endothelin induced hypertension and oxidative stress in rats. Hypertens Res 2004;27:493-500
13. Nimata M, Kishimoto C, Yuan Z, Shioji K. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 2004;259:217-22 (Pubitemid 38519234)
14. Mollnau H, Wendt M, Szöcs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 2002;90:58-65
15. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
16. Shirai K, Watanabe K, Ma M, Wahed MI, Inoue M, Saito Y, Suresh PS, Kashimura T, Tachikawa H, Kodama M, Aizawa Y. Effects of angiotensin-II receptor blockers candesartan cilexetil in rats with dilated cardiomyopathy. Mol Cell Biochem 2005;269:137-42
17. Tachikawa H, Kodama M, Hui L, Yoshida T, Hayashi M, Abe S, Kashimura T, Kato K, Hanawa H, Watanabe K, Nakazawa M, Aizawa Y. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis. J Cardiovasc Pharmacol 2003;41:S105-10
18. Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol 2008;581:121-31
19. Watanabe K, Ohta Y, Nakazawa M, Higuchi H, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 2000;130:1489-95
20. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei-Kim, Matsumota K, Nakamura T, Higaki J, Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-52
21. Yamaguchi K. Effects of water deprivation on immunoreactive angiotensin II levels in plasma, cerebroventricular perfusate and hypothalamus of the rat. Acta Endocrinol 1981;97:137-44 (Pubitemid 11074379)
22. Phillips MI, Stenstrom B. Angiotensin II in rat brain comigrates with authentic angiotensin II in high pressure liquid chromatography. Circ Res 1985;56:212-9
23. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-8
24. Weber KT, Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 1991;12:61-9
25. Sun Y, Zhang JQ, Zhang J, Ramires FJ. Angiotensin II, transforming growth factor-b1 and repair in the infarcted heart. J Mol Cell Cardiol 1995;30:1559-69
26. Jesmin S, Sakuma I, Hattori Y, Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler Thromb Vasc Biol 2003;23:2021-6
27. Smits JF, van Krimpen C, Schoemaker RG, Cleutjens JP, Daemen MJ. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772-8
28. Cleutjens JP. The role of matrix metalloproteinases in heart disease. Cardiovasc Res 1996;32:816-21
29. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001;87:10C-17C
30. Takenaka H, Kihara Y, Iwanaga Y, Onozawa Y, Toyokuni S, Kita T. Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension. J Mol Cell Cardiol 2006;41:989-97
31. Hayashi T, Sohmiya K, Ukimura A, Endoh S, Mori T, Shimomura H, Okabe M, Terasaki F, Kitaura Y. Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 2003;89:1236-42
32. Pool JL, Glazer R, Chiang YT, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999;13:275-81 (Pubitemid 29187010)
33. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46
34. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang-II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001;24:641-6
35. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin-II antagonist losartan in essentional hypertension. Am J Hypertens 1994;7:1041-44
36. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac angiotensin II to ventricular remodeling in rats with myocardial-infarcted rats. J Am Coll Cardiol 1993;21:301A
37. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231:1145-7
38. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994;72:561-6 (Pubitemid 2165255)
39. Seko Y. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. Clin Sci 2006;110:379-86
40. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, Takeya M, Yoshimura T, Matsushima K, Takeshita A. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000;101:305-10
41. 1R antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007;152:1042-8